Minute Insight: Current Testing Technologies Can Detect The Omicron Variant
As fears about vaccine escape grow, test manufacturers have been quick to assert that their tests can spot the new Omicron variant of SARS-CoV-2
You may also be interested in...
The company expects the major commercial collaboration and geographical roll-out will lead to increased adoption of Agendia’s breast cancer diagnostics.
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022. Here are some highlights from the in vitro diagnostics companies that presented on the first two days of the meeting.
Medtech Insight spoke to Rutger Zietsma, Manus Neurodynamica’ CEO, to learn about the next commercial steps for the company's Neuromotor Pen for differential diagnosis of neuromotor impairment.